Articles published by Landos Biopharma, Inc.

Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder
From Landos Biopharma, Inc.
Via GlobeNewswire
Tickers LABP
Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization
From Landos Biopharma, Inc.
Via GlobeNewswire
Tickers LABP
Landos Biopharma Provides Comprehensive Update on Clinical Development Plans
From Landos Biopharma, Inc.
Via GlobeNewswire
Tickers LABP
Landos Biopharma Announces $16.7 Million Private Placement Financing
From Landos Biopharma, Inc.
Via GlobeNewswire
Tickers LABP
Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update
From Landos Biopharma, Inc.
Via GlobeNewswire
Tickers LABP
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.